Abstract
Helicobacter pylori (H. pylori) is associated with gastric mucosal injury, gastric ulcer and other gastrointestinal diseases. Resistance of H. pylori to antibiotics has become an obstacle to clinical eradication therapy. Bovine lactoferrin (bLF) has a broad spectrum of antibacterial effects, high safety and no side effects, which may be conductive to improving the dilemma of antibiotic resistance. We aimed to explore the bactericidal effect of bLF on resistant H. pylori and the protective effect on gastric mucosal injury. In vitro experiments demonstrated that bLF has obvious antibacterial effect on resistant H. pylori and synergistic antibacterial effect when combined with clarithromycin. The MIC and MBC of bLF against resistant H. pylori ranged from 1.25 to 5 mg mL−1. In vivo experiments showed that bLF could improve the degree of gastric mucosa injury, decrease the area of gastric ulcer. Results indicate that bLF has a wide clinical application prospect in medical field.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
